Oryzon Genomics S.A.
ORYZF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.06 | 17.21 | -0.55 | 1.05 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 0.00 | 656.96 | 0.00 | 19.92 |
| Quality | ||||
| ROIC | 0.00% | -0.05% | 0.00% | 1.98% |
| Gross Margin | 0.00% | 96.51% | 0.00% | 95.89% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -20.66% | -20.66% | -20.58% | -20.58% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -58.67 | 0.00 | 1.05 |
| Interest Coverage | 0.00 | 0.00 | -14.61 | 2.25 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 24.34 | 0.00 | 101.47 |
| Cash Conversion Cycle | 0.00 | -1,244.88 | 0.00 | -615.45 |